ArticleScientific reports2025
Development of a novel liquid chromatography-tandem mass spectrometry based enzymatic assay of 5,10-methylenetetrahydrofolate reductase.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency is the most common folate metabolism disorder. MTHFR is a key enzyme in the folate cycle that catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-methyl THF). A definitive diagnosis of MTHFR deficiency relies on enzymatic studies of fibroblasts and/or molecular genetic analyses. The accurate measurement of the MTHFR enzyme activity is crucial for diagnosing and predicting disease severity, which is traditionally performed using high-performance liquid chromatography with fluorescence detection. We developed a novel method for assessing the MTHFR enzymatic activity using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The MTHFR enzymatic reaction was conducted in fibroblasts, and the product, 5-methyl THF, was quantified by LC-MS/MS. The MTHFR activity was evaluated in 13 control individuals and five individuals with MTHFR deficiency. The 5-methyl THF concentration was successfully measured in all cases, and the validation trial demonstrated adequate accuracy and precision. Control fibroblasts exhibited an MTHFR activity ranging from 240.1 to 624.0 pmol/min/mg protein (mean = 338.5 pmol/min/mg), while MTHFR-deficient fibroblasts showed a markedly lower activity (2.99-51.3 pmol/min/mg protein). Although our study is associated with some limitations, we present a sensitive and reliable LC-MS/MS based assay for diagnosing MTHFR deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.